Supplementary Table 1 ǀ The prognostic importance of ploidy in patients with invasive breast cancer
Study (year of
publication)
Method of
ploidy
measurement
Number
of
patients
Tryggvadottir et al.
(2013)S1
Tryggvadottir et al.
(2013)S1
FCM-A
2,752
FCM-A
215
Pinto et al.
(2013)S2
Ermiah et al.
(2012)S3
Karra et al.
(2012)S4
Morand et al.
(2009)S5
Li et al. (2008)S6
FCM-F
Railo et al.
(2007)S7
Pinto et al.
(2006)S8
Kronenwett et al.
(2006)S9
Moureau-Zabotto
et al. (2005)S10
Pinto et al.
(2003)S11
Tsutsui et al.
(2003)S12
Bagwell et al.
(2001)S13
Chassevent et al.
(2001)S14
Azua-Romeo et al.
(2001)S15
Duigou et al.
(2000)S16
Mandard et al.
(2000)S17
Tumour
stage
and/or
grade
All
N0
(%)
Diploid
(%)
Followup
duration
End
point
P value
HR
58
29
9.5 yrs
CSS
M: P = 0.04
1.20
48
39
9.5 yrs
CSS
M: P = 0.001
0.31
393
BRCA2mutant
tumours
I–III
56
41
134 mo
DSS
M: P = 0.002
2.01
ICMsuspension
ICM-imprint
104
NA
NA
17
51 mo
DFS
M: P = 0.02
NA
603
I–III
53
26
10.2 yrs
CSS
M: P = 0.001
2.5
FCM-F
69
84
79
93 mo
DFS
U: P = 0.03
NA
ICM-imprint
378
T1–T2, G1–
G2
NA
9 yrs
MFS
NA
NA
FCM-A
212
T1N0M0
100
55
15.9 yrs
CSS
NA
FCM-F
135
100
NA
58 mo
DFS
ICM-imprint
890
pT–T2N0
G2
All
U: P = 0.02 at 5 yrs;
NS at 10 yrs
M: P = 0.007
39
32
8.9 yrs
CSS
NS
NS
FCM-F
271
I–II, T1/T2
60
47
64 mo
MFS
M: P = 0.008
2.1
ICM
392
II–IV
NA
29
81 mo
OS
NA
NA
FCM
998
NA
NA
NA
42 mo
DFS
M: P <0.0001
NA
FCM-A
961
All N0
100
33
10 yrs
RFS
M: P = 0.000005
1.8
FCM-F
633
65
31
69 mo
DFS
NS
NS
ICM
500
T1–2 N0–1
M0
NA
NA
NA
15 yrs
NA
NA
NA
FCM
1,485
NA
NA
35
51 mo
281
T1–T2
88
48
82 mo
U: P = <0.0001 (OS)
U: P = 0.001 (MFS)
U: P = 0.0004 (RFS)
NS
NA
ICM
OS,
MFS,
RFS
OS,
DFS
32
Abbreviations: CSS, cancer-specific survival; DFS, disease-free survival; DSS, disease-specific survival;
FCM, flow cytometry; FCM-A, flow cytometry using archival material; FCM-F, flow cytometry using
fresh or frozen material; G, grade; HR, hazard ratio; ICM, image cytometry; M, multivariate analysis;
MFS, metastasis-free survival; mo, months; N0, lymph-node negative; NA, not applicable; NS, not
significant; OS, overall survival; RFS, recurrence-free survival; U, univariate analysis; yrs, years.
S1.
S2.
S3.
S4.
Tryggvadottir, L. et al. Tumour diploidy and survival in breast cancer patients with BRCA2
mutations. Breast Cancer Res.Treat. 140, 375-384 (2013).
Pinto, A.E. et al. DNA ploidy is an independent predictor of survival in breast invasive ductal
carcinoma: a long-term multivariate analysis of 393 patients. Ann.Surg.Oncol. 20, 1530-1537
(2013).
Ermiah, E. et al. Prognostic significance of DNA image cytometry in Libyan breast cancer.
Oncology 83, 165-176 (2012).
Karra, H. et al. Securin predicts aneuploidy and survival in breast cancer. Histopathology 60,
586-596 (2012).
16.7
NS
S5.
S6.
S7.
S8.
S9.
S10.
S11.
S12.
S13.
S14.
S15.
S16.
S17.
Morand, C. et al. Pure mucinous carcinomas of the breast: prognostic study including DNA
flow cytometry. Cytometry B Clin. Cytom. 76, 56-62 (2009).
Li, L. et al. Genomic instability and proliferative activity as risk factors for distant metastases
in breast cancer. Br. J. Cancer 99, 513-519 (2008).
Railo, M., Lundin, J., Haglund, C., von Smitten, K. & Nordling, S. Ki-67, p53, ER receptors,
ploidy and S phase as long-term prognostic factors in T1 node-negative breast cancer.
Tumour Biol. 28, 45-51 (2007).
Pinto, A.E., Andre, S., Pereira, T., Silva, G. & Soares, J. DNA flow cytometry but not
telomerase activity as predictor of disease-free survival in pT1-2/N0/G2 breast cancer.
Pathobiology 73, 63-70 (2006).
Kronenwett, U. et al. Genomic instability and prognosis in breast carcinomas. Cancer
Epidemiol.Biomarkers Prev. 15, 1630-1635 (2006).
Moureau-Zabotto, L. et al. Combined flow cytometry determination of S-phase fraction and
DNA ploidy is an independent prognostic factor in node-negative invasive breast carcinoma:
analysis of a series of 271 patients with stage I and II breast cancer. Breast Cancer Res.Treat.
91, 61-71 (2005).
Pinto, A.E., Andre, S., Mendonca, E., Silva, G. & Soares, J. Overall survival in advanced breast
cancer: relevance of progesterone receptor expression and DNA ploidy in fine-needle
aspirates of 392 patients. Int. J. Biol. Markers 18, 7-12 (2003).
Tsutsui, S. et al. Prognostic significance of the combination of biological parameters in breast
cancer. Surg. Today 33, 151-154 (2003).
Bagwell, C.B. et al. Optimizing flow cytometric DNA ploidy and S-phase fraction as
independent prognostic markers for node-negative breast cancer specimens. Cytometry 46,
121-135 (2001).
Chassevent, A. et al. S-phase fraction and DNA ploidy in 633 T1T2 breast cancers: a
standardized flow cytometric study. Clin Cancer Res. 7, 909-917 (2001).
Azua-Romeo, J., de Azua-Blanco, J. & Romeo, P. Image cytometry in nonproliferative
fibrocystic breast changes. Ploidy evaluation and epidemiologic study.
Anal.Quant.Cytol.Histol. 23, 129-134 (2001).
Duigou, F., Herlin, P., Marnay, J. & Michels, J.J. Variation of flow cytometric DNA
measurement in 1,485 primary breast carcinomas according to guidelines for DNA histogram
interpretation. Cytometry 42, 35-42 (2000).
Mandard, A.M. et al. Prognostic value of DNA cytometry in 281 premenopausal patients with
lymph node negative breast carcinoma randomized in a control trial: multivariate analysis
with Ki-67 index, mitotic count, and microvessel density. Cancer 89, 1748-1757 (2000).